Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

15 trials with published results (11%)

Research Maturity

71 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

8.1%

11 terminated out of 136 trials

Success Rate

86.6%

+0.1% vs benchmark

Late-Stage Pipeline

37%

50 trials in Phase 3/4

Results Transparency

21%

15 of 71 completed with results

Key Signals

15 with results87% success11 terminated

Data Visualizations

Phase Distribution

104Total
Not Applicable (29)
Early P 1 (1)
P 1 (6)
P 2 (18)
P 3 (17)
P 4 (33)

Trial Status

Completed71
Unknown24
Recruiting12
Terminated11
Withdrawn8
Not Yet Recruiting7

Trial Success Rate

86.6%

Benchmark: 86.5%

Based on 71 completed trials

Clinical Trials (136)

Showing 20 of 20 trials
NCT07561957Not ApplicableRecruiting

A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines

NCT00977977Phase 2Recruiting

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

NCT05196035Phase 3Recruiting

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05457283Phase 3Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT07219121Phase 4RecruitingPrimary

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07224776Phase 1Not Yet Recruiting

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

NCT07431931Not ApplicableNot Yet Recruiting

Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria

NCT07358520Phase 4Not Yet RecruitingPrimary

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

NCT07355361Phase 2Not Yet RecruitingPrimary

Huaier Granule and Proteinuria

NCT07331259Not Yet Recruiting

CHART-C3G/CLNP023B12011

NCT07260292Not ApplicableCompleted

KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.

NCT04752293Recruiting

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT01094327RecruitingPrimary

Proteinuria in Pre and Post Transplant

NCT07030894Phase 4Recruiting

Nefecon and Ambrisentan in IgA Nephropathy

NCT07150338Completed

Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease

NCT06923709Phase 2Recruiting

Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease

NCT06867471Not ApplicableRecruiting

Effects of Exogenous Ketosis on Proteinuria and Renal Function

NCT00817037Phase 2Completed

Sitaxsentan in Proteinuric Chronic Kidney Disease

NCT06792448Not Yet Recruiting

Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study

NCT05759754Not ApplicableCompletedPrimary

Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease

Scroll to load more

Research Network

Activity Timeline